Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-A "healthier rally" ahead?

Tue, 27th Mar 2018 11:57

* European stocks rise 1.4 pct * Wall Street, Asia surged on China-U.S. trade talks March 27 - Welcome to the home for real-time coverage of European equity markets brought toyou by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger toshare your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net A "HEALTHIER RALLY" AHEAD? (1052 GMT) We've had a "healthy" correction, but could the recent sell-off lead to a "healthy" rally? Barclays' equity derivative strategists see the possibility of a trade war keeping themarket on edge, which they say would allow some of the "excessive exuberance" to abate. Theypoint to a cooling in equity market valuations since the recent sell-off (see Barclays' chartsbelow) and sentiment among retail investors moderating. "In one sense, we view this as a healthy development, given it would provide an outlet forsome of the excess exuberance," say Barclays' strategists in a note. One thing to watch is how fast volatility normalises. Barclays notes that if this isgradual, it would be a sign that market sentiment was cautious and herald a return to "the“normal” grinding rally". "If equities do not recover sharply, we believe valuations have a better chance ofnormalising, which would set the stage for a healthier subsequent rally," Barclays concludes. (Kit Rees) ***** KEEPING TABS ON THE S&P'S 200-DAY MOVING AVERAGE (1005 GMT) Investors are increasingly looking at the S&P 500's 200-day moving average,especially after the two big sell-offs that roiled markets this year saw the bears surrender tothe bulls just when the U.S. benchmark index hit that level. The S&P fell more than 6 percent last week to end a tick above the 200-day average, but onMonday it staged a powerful bounce, indicating how crucial that level has become for the market. Going forward, any breach below it may well be seen as a negative signal and JCI Capitalfund manager Alessandro Balsotti believes that from now on investors will be monitoring it evenmore "religiously". And what about Europe? Well it's a different story: the STOXX 600 has been tradingbelow the 200-day average since early February. (Danilo Masoni) ***** SHARES SHRUG OFF WEAK EUROPEAN DATA BUT "PEAK GROWTH" NARRATIVE BUILDS (0950 GMT) Economic sentiment in the euro zone slipped for a third month in a row in March as managersin manufacturing, services and retail became slightly less optimistic, European Commission datajust showed. But stocks are taking this in their stride and have even accelerated their risefrom 1.2 percent to 1.5 percent since the data was published. A whole bunch of research this morning ahead of the publication noted, like DNB's dailynote, that "Eurozone macro data surprises have been more negative than positive recently" andthat "growth is strong, but no longer accelerating". For CMC Markets, "the beginning of possible micro fissures in the European growth story"and "momentum indicators ... flashing warning signs" may be an explanation as to why Europeanmarkets are having a hard time keeping up with their U.S. counterparts. In a strategy note on European equities this morning, HSBC said that its "economics team'sview of GDP growth momentum fading through the course of this year" backed investing in longerduration fixed income and in stocks with higher dividend yield for their "defensive attributes". On the trading floor however the consensus seems to be that the euro zone's economic healthstill backs an optimistic view of its shares. There can be "a lot of noise in macro data in thenear-term", Chris Dyer, director of global equity at Eaton Vance just told us. "Generally we think the European economy is on a good footing", Dyer, who is overweightEuropean equities, said, adding that the weakness in economic data will only become a concern ifit continues. Here's a chart by DNB showing the loss of growth momentum in Europe: (Helen Reid and Julien Ponthus) ***** OPENING SNAPSHOT: EUROPEAN STOCKS BOUNCE (0727 GMT) European shares are joining in a global relief rally in risk assets as trade tensions ease.Sectors which were hit hardest over the past few sessions, such as autos, basicresources and tech, are the biggest gainers early on. The biggest individual mover so far is France's Casino, which has jumped around 6percent after its Monoprix chain agreed to sell products via Amazon. This shows just how crucialit is for companies to demonstrate that they are keeping up with the times and exploring onlineopportunities. Regarding the spreadbetters and ESMA's restrictions on CFDs, it's a mixed bag following adecidedly negative start, with IG down slightly but both CMC and Plus500 making gains. Here's your opening snapshot: (Kit Rees) ***** WHAT'S ON THE RADAR FOR THE OPEN (0649 GMT) European stocks are set to surge with futures climbing 1.4 to 2.2 percent across the majorbenchmarks, riding the wave of rising equities worldwide after Wall Street indices had theirstrongest day in years as investors bet on a trade war détente. Retail stocks will be ones to watch after French supermarket group Casino struck a deal withAmazon to make groceries from its Monoprix chain of stores available on Amazon’s Prime Nowservice to Parisian customers this year. The partnership extends Amazon’s reach into the European grocery market, and while Casinoshares are seen rising 3 to 5 percent, the news could shake investors’ confidence in retailnames that are more behind the curve. In M&A news, GlaxoSmithKline shares are expected to rise 3 to 4 percent after the pharmacompany announced it was buying out Novartis’ stake in their consumer healthcare joint venturefor $13 billion. Novartis is seen up 1 percent. Another corporate break-up story from Akzo Nobel which is to sell its Specialty Chemicalsbusiness for $12.6 billion to U.S. private equity firm Carlyle Group and Singapore’s GIC –ending the simplification effort which began as the paint maker sought to evade a takeover fromPPG in April 2017. Its shares are set to rise 2 to 4 percent. Spreadbetters such as IG Group, CMC Markets and Plus500 are seen down 2 percent premarketafter a move from European markets regulator ESMA to crack down on contract-for-difference (CFD)trades offered to retail clients. (Helen Reid) ***** MORNING HEADLINE ROUND-UP (0637 GMT) Here's a round-up of key headlines for European companies this morning - note the news thatCasino's Monoprix is going to be teaming up with Amazon to sell groceries on Prime Nowin Paris. Casino's shares are seen up as much as 5 percent premarket. GSK buys Novartis stake in consumer healthcare venture for $13 bln H&M Q1 pretax dives in line with expectations, flags more markdowns Deutsche Bank seeks to replace CEO with Goldman executive -report Amazon wins grocery foothold in France through Monoprix deal Galliford Try to raise 158 mln stg to cover Carillion project costs Nordex sees lower sales, margins as wind industry tightens Akzo Nobel to sell unit to Carlyle, GIC for 10.1 bln euros (Kit Rees) ***** EUROPEAN STOCK FUTURES SURGE (0610 GMT) Futures for the major European stock markets have opened sharply higher, rising 1.1 to 1.8percent with the DAX in the lead, as investors place bets on a strong bounce at the open. Meanwhile analysts are still mulling what caused the late-afternoon slump in sharesyesterday. Here's Peel Hunt strategist Ian Williams: "The trigger was not immediately obvious with neither further strength in the euro, or thelatest wave of Russian diplomatic expulsions, especially convincing reasons for such a move. Amore worrying interpretation is that investors may be taking advantage of even the most modestof rallies to lighten their equity exposure." If Williams is right we may see a volatile session today as well - but for the moment allsigns are pointing to a strong rebound for the European market. (Helen Reid) ***** BULLS TO KEEP THE UPPER HAND (0548 GMT) Goldman Sachs' Bear/Bull indicator is above 70%, a level normally associated with animminent bear market (see below). But the GS team led by Peter Oppenheimer reckons relativelyattractive equity valuations will protect markets from a big drawdown, at least for now. There's also a wide spread in the underlying variables behind the indicator: very low levelsof unemployment and strong growth momentum are normally accompanied with "tighter monetarypolicy, a flatter yield curve and rising core inflation," notes GS. "But these remain subduedand without these risks rising, the prospect of a recession and 'cyclical' bear market is low." Valuation meanwhile is becoming less of a risk, they add - the forward consensus PE for theMSCI AC World is back to its 1990 average and below its average excluding Tech stocks. Highvaluations are mostly confined to the U.S. market. Furthermore, free cash flow yields have increased along with P/E ratios, and the total cashreturn from equities (dividend yield + buyback yield) has risen in most markets. So the overall message from GS is: don't panic! The bulls will prevail, at least for now... (Helen Reid) ***** MORNING CALL: EUROPEAN STOCKS TO BOUNCE BACK STRONGLY(0520 GMT) Good morning and welcome to Live Markets. Risk appetite is back! European stocks are called to open strongly higher today after a weakclose yesterday. They're being pushed up by the equities rally on Wall Street and in Asiaovernight greeting news that the U.S. and China are holding behind-the-scenes trade talks. White House officials are asking China to cut tariffs on imported cars, allow foreignmajority ownership of financial services firms and buy more U.S.-made semiconductors, accordingto a person familiar with the discussions. Asian shares bounced back overnight with the Nikkei up 1.7 percent and Chinese blue-chipsgaining 1.2 percent. The gains came after a stellar session on Wall Street with the Dowdelivering its third-biggest point gain ever, jumping 2.8 percent, while the S&P 500 gained 2.7percent and the Nasdaq surged up 3.3 percent. A negative currency effect could weigh on European stocks today, though, with the euro stillnear the six-week high against the dollar it touched yesterday. It had its biggest one-daypercentage gain since June 2017 yesterday. Spreadbetters call the DAX 183 points higher at 11,971, the CAC 40 up 60 points at 5,127,and the FTSE 100 78 points higher at 6,966. (Helen Reid) ***** (Reporting by Helen Reid, Danilo Masoni, Julien Ponthus and Kit Rees)
More News
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.